title: New advances in targeted gastric cancer treatment.
abstract: Despite a decrease in incidence over past decades, gastric cancer remains a major global health problem. In the more recent period, survival has shown only minor improvement, despite significant advances in diagnostic techniques, surgical and chemotherapeutic approaches, the development of novel therapeutic agents and treatment by multidisciplinary teams. Because multiple genetic mutations, epigenetic alterations, and aberrant molecular signalling pathways are involved in the development of gastric cancers, recent research has attempted to determine the molecular heterogeneity responsible for the processes of carcinogenesis, spread and metastasis. Currently, some novel agents targeting a part of these dysfunctional molecular signalling pathways have already been integrated into the standard treatment of gastric cancer, whereas others remain in phases of investigation within clinical trials. It is essential to identify the unique molecular patterns of tumours and specific biomarkers to develop treatments targeted to the individual tumour behaviour. This review analyses the global impact of gastric cancer, as well as the role of Helicobacter pylori infection and the efficacy of bacterial eradication in preventing gastric cancer development. Furthermore, the paper discusses the currently available targeted treatments and future directions of research using promising novel classes of molecular agents for advanced tumours.
authors: Daniela Cornelia Lazăr, Adrian Goldiş, Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy, "Victor Babeş", 300041 Timişoara, Timis County, Romania.
authors: Daniela Cornelia
authors: DC
authors: Lazăr
authors: Daniela Cornelia Lazăr, Adrian Goldiş, Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy, "Victor Babeş", 300041 Timişoara, Timis County, Romania.
authors: Sorina
authors: S
authors: Tăban
authors: Daniela Cornelia Lazăr, Adrian Goldiş, Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy, "Victor Babeş", 300041 Timişoara, Timis County, Romania.
authors: Marioara
authors: M
authors: Cornianu
authors: Daniela Cornelia Lazăr, Adrian Goldiş, Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy, "Victor Babeş", 300041 Timişoara, Timis County, Romania.
authors: Alexandra
authors: A
authors: Faur
authors: Daniela Cornelia Lazăr, Adrian Goldiş, Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy, "Victor Babeş", 300041 Timişoara, Timis County, Romania.
authors: Adrian
authors: A
authors: Goldiş
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017209:Apoptosis; D002453:Cell Cycle / Q000187:drug effects; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D007167:Immunotherapy; D007334:Insulin-Like Growth Factor I / Q000037:antagonists & inhibitors; D058990:Molecular Targeted Therapy; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000627:therapeutic use; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D017468:Receptors, Fibroblast Growth Factor / Q000037:antagonists & inhibitors; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D066246:ErbB Receptors; D007334:Insulin-Like Growth Factor I; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D019859:Proto-Oncogene Proteins c-met; D018719:Erb-b2 Receptor Tyrosine Kinases; D017468:Receptors, Fibroblast Growth Factor; D042461:Vascular Endothelial Growth Factor A
keywords: Chemotherapy; Clinical trials; Gastric cancer; Helicobacter pylori infection; New treatment advances; Targeted therapy